![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Indian Developers Begin Human Trials of Two COVID-19 Vaccines
Indian Developers Begin Human Trials of Two COVID-19 Vaccines
![India_shape.jpg](https://www.fdanews.com/ext/resources/test/Drug-Images4/India_shape.jpg?t=1600823036&width=430)
July 16, 2020
Two clinical trials of potential COVID-19 vaccines got under way in India this week.
Ahmedabad-based Zydus Cadila launched a phase 1/2 trial of its plasmid DNA-based vaccine candidate, ZyCoV-D, and Hyderabad-based Bharat Biotech began a study of Covaxin, an inactivated vaccine derived from a strain of the SARS-CoV-2 virus.
Both vaccines will be evaluated for safety, tolerability, and immunogenicity in more than 1,000 participants at multiple sites.
Upcoming Events
-
21Oct